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Abstract
AIM: To compare the recurrent bleeding a�ter endo-
scopic injection o� di��erent epinephrine volumes with 
hemoclips in patients with bleeding peptic ulcer.
METHODS: Between January 2005 and December 
2009, 150 patients with gastric or duodenal bleeding 
ulcer with major stigmata o� hemorrhage and nonbleed-
ing visible vessel in an ulcer bed (Forrest Ⅱa) were 
included in the study. Patients were randomized to re-
ceive a small-volume epinephrine group (15 to 25 mL 
injection group; Group 1, n  = 50), a large-volume epi-
nephrine group (30 to 40 mL injection group; Group 2, 
n  = 50) and a hemoclip group (Group 3, n  = 50). The 
rate o� recurrent bleeding, as the primary outcome, 
was compared between the groups o� patients included 
in the study. Secondary outcomes compared between 
the groups were primary hemostasis rate, permanent 
hemostasis, need �or emergency surgery, 30 d mortal-
ity, bleeding-related deaths, length o� hospital stay and 
trans�usion requirements.
RESULTS: Initial hemostasis was obtained in all pa-
tients. The rate o� early recurrent bleeding was 30% 
(15/50) in the small-volume epinephrine group (Group 
1) and 16% (8/50) in the large-volume epinephrine 
group (Group 2) (P  = 0.09). The rate o� recurrent 
bleeding was 4% (2/50) in the hemoclip group (Group 
3); the di��erence was statistically signi�icant with re-
gard to patients treated with either small-volume or 
large-volume epinephrine solution (P  = 0.0005 and P  
= 0.045, respectively). Duration o� hospital stay was 
signi�icantly shorter among patients treated with he-
moclips than among patients treated with epinephrine 
whereas there were no di��erences in trans�usion re-
quirement or even 30 d mortality between the groups.
CONCLUSION: Endoclip is superior to both small and 
large volume injection o� epinephrine in the prevention 
o� recurrent bleeding in patients with peptic ulcer.  
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Peptic ulcer disease accounts for 50% to 70% of  cases 
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of  acute nonvariceal upper gastrointestinal bleeding 
(UGIB)[1,2]. Initial haemostatic rates of  80% to almost 
100% can be achieved with various endoscopic tech-
niques. However, after initial control, bleeding recurs in 
10% to 30% of  patients[3].
Among various endoscopic techniques a recent Inter-
national consensus on nonvariceal UGIB recommends 
combination therapy with clear statement that epineph-
rine injection alone provides suboptimal efficacy and 
should be used in combination with another methods[4]. 
However, several recent studies found injection of  a 
large volume of  epinephrine to be superior to injection 
of  a small epinephrine volume with respect to recurrent 
bleeding from peptic ulcer[5,6]. Since epinephrine injection 
is effective (initial hemostasis obtained with epinephrine 
injection range from 85% to 100%), safe, inexpensive 
and technically easy, the concept of  a beneficial effect of  
large volumes of  epinephrine in preventing recurrent ul-
cer bleeding seems to be very challenging. Therefore, the 
aim of  this prospective study was to compare the rates 
of  recurrent bleeding after endoscopic injection of  two 
different volumes of  an epinephrine solution (15-25 mL 
vs 30-40 mL) with endoscopic placement of  hemoclips in 
patients with peptic ulcer bleeding. Since it has been sug-
gested that the useful baseline factor for stratification in 
UGIB trials may be stigmata of  hemorrhage in an ulcer, 
we decided to include in the study only patients present-
ing with acute UGIB and endoscopically proven gastric 
or duodenal ulcer with visible vessel in an ulcer bed (For-
rest Ⅱa)[7].
MATERIALS AND METHODS
Between January 2005 and December 2009, consecutive 
patients presenting with acute UGIB were considered for 
this study. These patients were referred to the Emergency 
Unit of  the Department of  Internal Medicine at the “Se-
stre milosrdnice” University Hospital, Zagreb, Croatia 
and then if  necessary hospitalized at the Interventional 
Gastroenterology Unit at the same hospital. 
UGIB was suspected if  hematemesis, melena or he-
matochezia were seen and/or bloody nasogastric aspirate 
was observed. In all those patients upper gastrointes-
tinal endoscopy was performed within 6 h of  hospital 
admission. Patients were included only if  emergency 
endoscopy disclosed a gastric or duodenal bleeding ulcer 
with major stigmata of  hemorrhage (“coffee ground” 
material or blood in the stomach and/or duodenum) and 
nonbleeding visible vessel in an ulcer bed (Forrest Ⅱ
a)[8]. Exclusion criteria were as follows: major comorbid 
or terminal illness that made endoscopy hazardous; in-
ability or unwillingness to consent to endoscopy and 
endoscopic therapy; gastric malignancy; minor stigmata 
of  hemorrhage at endoscopy such as oozing from ulcer 
borders without a visible vessel, flat-pigmented spots, or 
clean ulcer base. Patients with gastric and duodenal ulcer 
with either an actively bleeding vessel (spurting or ooz-
ing; Forrest Ⅰ), or adherent clot (Forrest Ⅱb) were also 
excluded. 
Endoscopy was performed with standard upper endo-
scopes (GIF Q140 and GIF Q160, Olympus Optical Co., 
Japan). Endotherapy was carried out by the well-trained 
endoscopists, each with at least five years experience in the 
treatment of  patients with GI bleeding. Endoscopic char-
acteristics, including ulcer localization, ulcer size, and type 
of  stigmata, were recorded (Endobase, Olympus, Japan). 
Possible complications of  endoscopic treatment and 
complete study protocol were discussed with patients and 
their relatives, and written informed consent was obtained 
before endoscopy and entry into the trial. The ethics com-
mittee of  our hospital approved the treatment protocol. 
Randomization of  eligible patients was carried out at the 
time of  endoscopy by an individual uninvolved with the 
procedure who opened sealed numbered envelopes con-
taining treatment assignments generated with a computer 
randomization program. The treatment group allocation 
was then communicated to the endoscopist in the endos-
copy suite. Patients were randomized to a small-volume 
epinephrine group (15 to 25 mL injection group; Group 1), 
a large-volume epinephrine group (30 to 40 mL injection 
group; Group 2) and a hemoclip group (Group 3). In the 
small-volume epinephrine group (Group 1) 15 to 25 mL 
of  a 1:10 000 solution of  epinephrine was injected around 
the visible vessel (2-4 mL/injection at 2-3 mm from the 
visible vessel). In the large-volume epinephrine group 
(Group 2), 30-40 mL of  a 1:10 000 solution of  epineph-
rine was injected around the visible vessel at the ulcer bed 
as in the small-volume epinephrine group. Mechanical 
hemostasis was performed with stainless steel hemoclips 
(Olympus, Japan) as has been previously described[9,10]. 
During endoscopy and endotherapy, electrocardiographic 
monitoring was used to detect arrhythmias.
Once hemostasis was achieved the bleeding site was 
observed for at least 10 min and it was assessed by water 
irrigation at maximal pressure. Failure of  the initial he-
mostasis has been defined if  any hemorrhage occurred 
immediately (within 10 min) after initial endoscopic 
hemostasis. In these patients crossing over to the other 
treatment group was not allowed. In all patients two bi-
opsy specimens were taken from the gastric antrum and 
body, and the presence of  Helicobacter pylori (H. pylori) 
infection was assessed by histopathological examination 
of  the specimens. In patients with gastric ulcer in whom 
recurrent bleeding was not observed, control endoscopy 
was performed 4 d to 5 d after initial hemostasis and bi-
opsy specimens were obtained from the margins and base 
of  gastric ulcers to exclude malignancy. 
After initial endoscopic hemostasis, patients were hos-
pitalized and cared for by a physician who was blinded to 
the endoscopic treatment that had been delivered. Vital 
signs were monitored hourly whereas blood counts were 
observed every 6 h for the first 48 h and every 12 h to 
24 h thereafter. All patients were given acid suppressive 
therapy: pantoprazole 80 mg iv, (bolus) and then 40 mg 
iv, every 8 h for at least 48 h, followed by 40 mg daily by 
mouth, or esomeprazole 80mg iv, (bolus) and then 40 mg 
iv, every 8 h for at least 48 h, followed by 20 mg once 
a day by mouth. Shock was defined as a systolic blood 
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pressure of  less than 90mmHg with symptoms or signs 
of  organ hypoperfusion. 
Recurrent bleeding was defined as one or more signs 
of  ongoing bleeding, including fresh hematemesis or 
melena, hematochezia, aspiration of  fresh blood via naso-
gastric tube, instability of  vital signs, and a reduction of  
Hb by more than 2 g/dL over a 24 h period (early recur-
rence) or over a 7 d period (late recurrence) after initial 
stabilization of  puls, blood pressure and Hb concentra-
tion. If  recurrent bleeding was suspected, endoscopy was 
performed immediately. If  “coffee ground” material or 
blood in the stomach and/or duodenum has been found 
together with active bleeding or a fresh blood clot in the 
ulcer base were found, recurrent bleeding was considered 
confirmed. For ethical reasons, additional endoscopic 
methods for treatment of  recurrent bleeding were dis-
cussed with patients and their relatives and therapeutic 
option in all patients with recurrent bleeding was hemo-
clip application. Patients in whom endoscopic treatment 
or retreatment was unsuccessful underwent emergency 
surgery. 
The rate of  recurrent bleeding, as the primary out-
come, was compared between the groups of  patients 
included in the study. Secondary outcomes compared 
between the groups were primary hemostasis rate (defined 
as the absence of  hemorrhage occurred immediately af-
ter initial endoscopic hemostasis), permanent hemostasis 
(defined as the absence of  recurrent bleeding within the 
30 d period after initial or secondary endoscopic hemo-
stasis), need for emergency surgery, 30 d mortality and 
bleeding-related deaths, length of  hospital stay, and trans-
fusion requirements.
Statistical analysis
Base on assumption that injection of  a large-volume epi-
nephrine decreased the expected rate of  recurrent bleeding 
from 17.1% after injection of  small-volume epinephrine so-
lution to zero, 39 patients would have been needed in each 
group for a power of  80% and a significance level of  0.05[6].
Continuous data were summarized as mean [95% 
confidence interval (CI)]. The Student t test was used to 
compare the mean values of  continuous variables. The 
Pearson chi-square test and the Fisher exact test were 
used when appropriate for the comparison of  categorical 
variables. All analyses were performed with a statistical 
package (SPSS for Windows, United States). A P values 
less than 0.05 were regarded as statistically significant.
RESULTS
From January 2005 to December 2009, 150 patients were 
included in this study; they were randomly assigned to re-
ceive small-volume (15 to 25 mL) injection of  epinephrine 
(Group 1, n = 50), large-volume (30 to 40 mL) injection 
of  epinephrine (Group 2, n = 50), and hemoclip (Group 3, 
n = 50). During the same period a total of  1516 patients 
with UGIB were encountered; of  these 47.8% had gastric 
or duodenal bleeding ulcer, 41.2% had non-ulcer lesions 
(acute erosive gastropathy, portal hypertensive gastropa-
thy, malignancy, Mallory-Weiss tear, angiomata, Dieulafoy’
s lesion), 9.1% had esophageal or gastric variceal bleeding, 
and 1.9% had no source of  bleeding (Figure 1). Among 
the 161 patients with UGIB and endoscopically proven 
peptic ulcer with visible vessel (Forrest Ⅱa), randomly 
assigned to receive small-volume or large-volume of  epi-
nephrine, or hemoclip, 11 patients were excluded because 
they refused to participate in the study. 
Clinical and endoscopic data obtained for patients in-
cluded in the study are outlined in Table 1. There were no 
significant differences between the groups with respect 
to age, gender, ulcer size and location, positive H. pylori 
status, NSAID or alcohol consumption, shock, bleeding 
stigmata, history of  previous peptic ulcer or peptic ulcer 
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Table 1  Clinical and endoscopic characteristics of the patients 
at study entry  n  (%)
Group 1
(n  = 50)
Group 2 
(n  = 50)
Group 3 
(n  = 50)
Age (yr)  68 (40-96)  61 (30-92)  67 (40-94)
Gender (M/F)  31/19  33/17  34/16
Location of ulcer
   Stomach  26 (52)  23 (46)  28 (56)
   Duodenum  24 (48)  27 (54)  22 (44)
Ulcer size (cm)
   < 2  36 (72)  44 (88 )  37 (74)
   ≥ 2  14 (28)    6 (12)  13 (26)
Gastric content
   Blood  19 (38)  22 (44)  21 (42)
   Coffee ground  31 (62)  28 (56)  29 (58)
Shock    4 (8)    2 (4)    1 (2)
Hb level (g/dL) 9.3 (3.9-14.7) 9.0 (3.6-14.2) 9.4 (5.6-14.3)
Comorbid disease  36 (72)  35 (70)  33 (60)
NSAIDs  15 (30)  23 (46)  29 (58) 
Alcohol consumption  20 (40)  23 (46)  30 (60) 
Smoker’s  12 (24)  16 (32)  10 (20)
Previous ulcer disease  14 (28)  10 (20)  11 (22)
Previous ulcer bleeding  12 (24)  10 (20)    8 (16)
Continuous data are expressed as mean (95% CI). NSAIDs: Non-steroidal 
anti-inflammatory drugs.
Table 2  Clinical outcomes of endoscopic therapy  n  (%)
Group 1 Group 2 Group 3
Primary outcome
   Early recurrent bleeding 15 (30)   8 (16)    2 (4)c,b
   Stigmata
      Spurting      4 (26.7)      1 (12.5)   1 (50)
      Oozing      5 (33.3)   2 (25)   1 (50)
      Visible vessel   6 (40)      5 (62.5) 0
Secondary outcomes
   Initial hemostasis   50 (100)   50 (100)   50 (100)
   Permanent hemostasis 44 (88) 46 (92) 48 (96)
   Emergency surgery   6 (12) 4 (8) 2 (4)
   30-d mortality 3 (6) 0 (0) 4 (8)
   Blood transfusion (mL) 1041 (120-1997) 912 (0-2039) 840 (0-1893) 
   Hospital stays (d) 7.5 (1-14) 7.6 (1-15) 5.7(1-15)b,d
Continuous data are expressed as mean (95% CI). bP < 0.01 vs group 1; cP < 
0.05, dP < 0.01 vs group 2. Pearson χ2 test.
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bleeding, comorbid diseases or hemoglobin and hemato-
crit levels at admission. 
Clinical outcome data are summarized in Table 2. Initial 
hemostasis was obtained in all patients. In the small-volume 
epinephrine group (Group 1) the mean volume of  epineph-
rine injected was 19.1 mL (range, 16 to 25 mL) whereas in 
the large-volume epinephrine group (Group 2) the mean 
volume of  epinephrine injected was 37.9 mL (range, 30 to 
40 mL). Among patients endoscopically treated with hemo-
clips (Group 3), multiple clips (up to three) were needed in 
majority of  cases with a median of  1.6 clips per patient. 
The rate of  early recurrent bleeding was 30% (15/50) 
in the small-volume epinephrine group (Group 1) and 
16% (8/50) in the large-volume epinephrine group 
(Group 2); the difference did not reach statistical signifi-
cance (P = 0.09). The rate of  recurrent bleeding was 4% 
(2/50) in the hemoclip group (Group 3); the difference 
was statistically significant with regard to patients treated 
with either small-volume or large-volume epinephrine 
solution (P = 0.0005 and P = 0.045, respectively). Late 
recurrent hemorrhage was not observed in our patients. 
With regard to ulcer location and ulcer size as well, there 
were no significant differences in the rate of  early recur-
rent bleeding between the groups. Also, there were no 
differences in transfusion requirement or even 30 d mor-
tality between the groups. However, duration of  hospital 
stay was significantly shorter among patients treated with 
hemoclips than among patients treated with epinephrine 
(Table 2). There was no bleeding-related death or proce-
dure-related death. Three patients from Group 1 (causes 
of  death were colon malignancy in one patient, cardiac 
failure in one patient, and obstructive pulmonary disease 
with pneumonia in one patient) and four patients from 
Group 3 died (pulmonary embolism in two patients and 
myocardial infarction in one patient). Among patients 
from Group 2 no one died. One patient in whom large-
volume injection of  the epinephrine solution was admin-
istered (35 mL) required emergent surgery because of  a 
perforation.
Of  the 15 patients in the small-volume epinephrine 
group (Group 1), eight patients in the large-volume epi-
nephrine group (Group 2), and two patients in the hemo-
clip group (Group 3) who had recurrent bleeding, all were 
treated with hemoclips. Emergency surgery was performed 
in all patients in whom re-treatment with hemoclips did 
not produce hemostasis: six patients from group 1, three 
patients from Group 2, and two patients from Group 3. 
Majority of  patients in whom emergency surgery has been 
performed had duodenal ulcer located on the duodenal 
bulb posterior wall (Group 1, 5/6; Group 2, 2/3; Group 
3, 3/3, respectively). Successful permanent hemostasis was 
not statistically different among groups of  patients (Table 2).
Therapeutic efficacy of  the small-volume epineph-
rine vs large-volume epinephrine and hemoclips is given 
in Table 3. Small-volume vs large-volume epinephrine 
was not significant in NNT benefit prediction, although 
small-volume epinephrine (NNT = 4) and large-volume 
epinephrine (NNT = 9) showed different significant ben-
efits concerning hemoclip treatment. 
There were no procedure-related cardiovascular com-
plications in the three groups. Electrocardiographic 
monitoring did not record any serious cardiac arrhythmia 
except of  occasional sinus tachycardia and isolated su-
praventricular extrasystoles observed among all patients 
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Figure 1  Patients with upper gastrointestinal bleeding. UGIB: Upper gastrointestinal bleeding.
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treated with large-volume epinephrine injection. The 
number of  patients who complained of  epigastric pain 
during and/or immediately after the procedure of  en-
dotherapy was significantly higher in the large-volume 
epinephrine group (34/50) than in the small-volume epi-
nephrine (3/50) or hemoclips (2/50) groups (P < 0.001).
DISCUSSION
Emergency endoscopy is accepted as the method of  
choice in the early identification and treatment of  a bleed-
ing peptic ulcer[10]. A variety of  endoscopic hemostatic 
methods have been developed and all were found to be 
similarly effective[3,11]. Epinephrine as the most commonly 
used agent for endoscopic injection therapy has been 
demonstrated to be effective for initial hemostasis but 
appears less effective in preventing further bleeding than 
other monotherapies, and definitely is less effective than 
epinephrine followed by a second modality such as scle-
rosant or a thermal contact device[4,12]. However, when the 
analysis was restricted to studies that used routine second-
look endoscopy with re-treatment of  high-risk stigmata, 
epinephrine injection was not found to be less effective 
than other monotherapies or epinephrine followed by sec-
ond modality[12]. On the other hand, limited data indicate 
that injection of  a large volume epinephrine seems to be 
superior to injection of  a small epinephrine volume with 
respect to recurrent bleeding[5,6,13]. These studies suggested 
local tamponade is the major effect in sustained hemo-
stasis and that injection of  larger volumes of  epinephrine 
may be beneficial in preventing recurrent bleeding by 
prolonging the hemostatic effect of  mechanical compres-
sion. Lin et al[5] demonstrated that injection of  a large 
volume (13-20 mL) of  epinephrine can reduce the rate of  
recurrent bleeding in patients with high-risk peptic ulcer 
and is superior to injection of  lesser volumes (5-10 mL) 
of  epinephrine (15.4% vs 30.8%). Park et al[6] reported 
that injection of  35 to 45 mL of  a epinephrine solution 
was more effective in preventing recurrent bleeding than 
an injection of  15 to 25 mL of  the same solution (0% vs 
17.1%). Similar results have been found by Liou et al[13,14] 
demonstrated that injection of  a large volume (30 to 40 
mL) of  epinephrine significantly reducing the rebleeding 
rate in patients with active bleeding ulcer. 
The current study clarifies the low value of  endoscopic 
injection therapy with epinephrine alone in patients with 
peptic ulcer bleeding showing major stigmata of  hemor-
rhage (patients with endoscopically proven peptic ulcer 
with a visible vessel in an ulcer bed; Forrest Ⅱa). Dispari-
ties in inclusion criteria using Forrest classification, across 
the majority of  studies that demonstrated higher effective-
ness of  large volume diluted epinephrine injection signifi-
cantly limit the interpretation of  those results. Unlike many 
mentioned studies, this trial was carried out on adequate 
patient’s sample with clearly predefined groups of  patients. 
Our results have clearly shown that endoscopic ther-
apy with hemoclip represents safe and effective method, 
superior to both, small-volume (15 to 25 mL) and large-
volume (30 to 40 mL) injection of  diluted epinephrine in 
the prevention of  early recurrent bleeding from peptic 
ulcer. Reduction in recurrent hemorrhage rates observed 
among our peptic ulcer patients treated with hemoclip 
method positively affected length of  hospital stay, reflect-
ing the possibility of  significant cost savings. 
It has been postulated that possible mechanisms that 
underlie hemostasis in response to endoscopic injection 
of  diluted epinephrine are vasoconstriction, vessel com-
pression, and platelet aggregation[15,16]. Among these, me-
chanical compression of  the bleeding vessel is the most 
important factor with respect to initial hemostasis[6,16]. 
Therefore, it has been assumed that injection of  larger 
volumes of  diluted epinephrine may be beneficial in 
preventing recurrent peptic ulcer bleeding by prolonging 
the hemostatic effect of  mechanical effect and compres-
sion[5,6,14]. Despite the fact that previously mentioned as-
sumption has been indirectly confirmed by several stud-
ies demonstrating a significantly lower rate of  recurrent 
peptic ulcer bleeding following large volume epinephrine 
injection, we strongly believe that even sustained me-
chanical compression achieved by a larger volumes of  di-
luted epinephrine injection is not sufficiently sustained to 
produce vessel compression that will last enough to pro-
voke platelet aggregation in a greater extent, that would 
finally result vessel thrombosis. The results observed in 
this study indicate that local tamponade observed even 
after larger volumes of  diluted epinephrine injection was 
not effective as hemoclip for the preventing of  recurrent 
bleeding. This observation strongly suggested that vessel 
compression, produced by a hemoclip has an important 
role in the mechanisms involved in vessel occlusion, thus 
preventing the recurrent bleeding.
To our knowledge, this is the first prospective ran-
domized study comparing the rates of  the recurrent 
bleeding after endoscopic injection of  two different vol-
umes of  an epinephrine solution and mechanical endo-
scopic method in patients with UGIB and endoscopically 
proven peptic ulcer with nonbleeding visible vessel in an 
ulcer bed (Forrest Ⅱa). Our results have confirmed that 
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Table 3  Therapeutic efficacy of small-volume and large-volume epinephrine, and hemoclips in reducing 
recurrent bleeding (95% CI)
Recurrent bleeding rate (%) RRR (%) ARR (%) NNT 
Small-volume vs large-volume epinephrine    46.6 (-11.2-75.0) 14.0 (-2.6-30.3)   8.0 (37.7-3.3)
Small-volume epinephrine vs hemoclips   86.7 (51.7-96.5)   26.0 (12.3-40.4) 4.0 (2.5-8.1)
Large-volume epinephrine vs hemoclips 75.0 (9.0-23.0) 12.0 (0.2-25.0)     9.0 (4.0-476.0)
RRR: Relative risk reduction; ARR: Absolute risk reduction; NNT: Number needs to treat.
Ljubicic N et al . Hemoclips vs  epinephrine in ulcer bleeding
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endoclip is safe and effective method, pointing out to its 
superiority to both, small volume and large volume injec-
tion of  diluted epinephrine in the prevention of  early 
recurrent bleeding from peptic ulcer.
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hemorrhage rates observed among our peptic ulcer patients treated with hemo-
clip method positively affected length of hospital stay, reflecting the possibility of 
significant cost savings�� 
Peer review 
This is the paper in which authors compere two most commonly used 
hemostatic methods in  patients with bleeding peptic ulcer�� The sample size        
is ade�uate, in a uni�ue center�� �� detailed description is provided to allow 
other investigators to reproduce or validate. The statistical methods used are 
appropriate. The results provide sufficient experimental evidence or data to 
draw firm scientific conclusions�� The discussion is well organized and provide 
systematic theoretical analyses and valuable conclusions.
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